Lineage Cell Therapeutics (LCTX) EBIAT (2016 - 2025)
Historic EBIAT for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$29.8 million.
- Lineage Cell Therapeutics' EBIAT fell 88157.55% to -$29.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$67.7 million, marking a year-over-year decrease of 23595.33%. This contributed to the annual value of -$18.6 million for FY2024, which is 1339.01% up from last year.
- Lineage Cell Therapeutics' EBIAT amounted to -$29.8 million in Q3 2025, which was down 88157.55% from -$30.5 million recorded in Q2 2025.
- In the past 5 years, Lineage Cell Therapeutics' EBIAT registered a high of -$1.4 million during Q1 2021, and its lowest value of -$30.5 million during Q2 2025.
- Moreover, its 5-year median value for EBIAT was -$6.1 million (2022), whereas its average is -$9.2 million.
- Over the last 5 years, Lineage Cell Therapeutics' EBIAT had its largest YoY gain of 8314.09% in 2021, and its largest YoY loss of 152677.17% in 2021.
- Lineage Cell Therapeutics' EBIAT (Quarter) stood at -$29.0 million in 2021, then skyrocketed by 78.08% to -$6.4 million in 2022, then increased by 24.85% to -$4.8 million in 2023, then surged by 31.46% to -$3.3 million in 2024, then tumbled by 809.9% to -$29.8 million in 2025.
- Its EBIAT stands at -$29.8 million for Q3 2025, versus -$30.5 million for Q2 2025 and -$4.1 million for Q1 2025.